HHS & Healthcare Contracts Intelligence — April 30, 2026

$75,505,831 already outlayed with 107 subawards at $63,748,654 signals active biotech R&D execution under CARB-X, providing stable nonprofit funding through 2029.

Unknown competition signal for Trustees of Boston University $150,780,000 BARDA award under full and open competition, with re-compete potential post-2029.

Uncertainty on exercising options to access additional $135M toward $285,780,000 ceiling for Trustees of Boston University BARDA R&D contract.

Trustees of Boston University BARDA contract offers path to $285,780,000 total via options and potential 2032 extension in antibacterial biotech R&D.

HHS BARDA's $150,780,000 award to Trustees of Boston University (NAICS 541714, PSC AN41) with $63,748,654 in 107 subawards demonstrates ongoing civilian investment in basic biotech research.

{"entity"=>"Trustees of Boston University", "reason"=>"$150,780,000 BARDA contract with $75,505,831 outlayed and ~$75M remaining obligation plus $135M options potential.", "trigger"=>"Remaining obligation progress; option exercises to 2029/2032 ends"}

{"entity"=>"HHS BARDA subawards", "reason"=>"107 subawards totaling $63,748,654 indicate subcontracting dispersion in antibacterial R&D.", "trigger"=>"Subaward performance and spending to 2029 contract end"}